The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 5.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 27%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (5 analysts) rates it none, with a mean price target of $109.
Interparfums, Inc.
IPAR · Nasdaq · USD · Market cap $3.7B · 662 employees
Interparfums, Inc., together with its subsidiaries, manufactures, markets, and distributes a range of fragrances and fragrance related products in the United States and internationally.
PASS · Titan Ethical · score 70.0At the last full screen
2026-08-26
Screened 2026-08-26 · the tape above runs as of 22:12 UTC · 11 Sep · two dates, stated on purpose · verdict and workings shown in full · never trimmed
This name holds its markdown label.
Interparfums, Inc. holds its Markdown at $116.67. The statistical read favours the buyers, held for 5 days.
| Phase | Markdown · caution |
| Quantitative state | The statistical read favours the buyers, held for 5 days |
| Price at the screen | $116.67 |
| Valuation | 22.31 trailing · 22.42 forward price to earnings |
| Values screen | PASS · score 70.0 |
| Beta | 1.15 |
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 13.10% | Below 33% | Interest-bearing debt is just 13.1% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 8.65% | Below 33% | Cash held in interest-bearing accounts and securities is 8.6% of assets, under the one-third limit. | Pass |
| Receivables | 30.20% | Below 49% | Money owed to the company is 30.2% of assets, under the 49% limit. | Pass |
| Revenue purity | 0.26% | Below 5% | Only 0.3% of revenue comes from non-compliant sources, under the 5% line. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
What the Numbers Say It Is WorthThe Fair Value Range
Fair value range in USD, drawn from the 2026-08-26 screen. The gold marker is the market price at the same screen. The price runs 23.4% above the base estimate.
Third-party analyst targets: 6 covering, consensus Hold. The average target sits +11% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & ProjectionsWhere it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-08-26 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsPerfume Bottles Sell But Shares Do Not
Every time a shopper picks up a licensed fragrance in a department store or duty free, Interparfums earns a slice of that sale through its European and US operations. The business runs at a solid 20 percent return on equity and clears an 11 percent profit margin, yet revenue is growing just 2 percent a year. At 22 times forward earnings the shares sit well above our fair value of 89 dollars, leaving a negative margin of safety and no opportunity rating.
We pass for the simple reason that price matters. The market has bid the stock to 123 dollars on a strong buy consensus, but that valuation leaves no room for the modest growth on offer. Low top line expansion in a competitive licensing business rarely justifies such multiples for long.
Currency moves, fashion shifts and the loss of key fragrance contracts remain real threats that could compress margins further. The ethical screen is clear, yet the numbers still point to an expensive defensive name rather than a bargain.
Analysis, not advice.
| Forward P/E | 22.4xexpensive even after accounting for its growth |
| Trailing P/E | 22.3xa premium valuation |
| EPS, trailing | 5.23 |
| EPS, forward | 5.20 |
| Revenue growth | +2.1%slow but positive growth |
| Profit margin | 11.2%thin but positive margins |
| Return on equity | 19.1%a solid return on shareholder capital |
| FCF yield | 5.88% |
| Dividend yield | 314.00% |
| Debt to equity | 0.15minimal debt: a conservative balance sheet |
| Current ratio | 3.31comfortably covers its short-term bills |
| Beta | 1.15moves a little more than the market |
| Short interest, float | 0.10% |
| 52-week range | 77.21 - 129.29 |
| Market cap | $3.7B |
| Employees | 662 |
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeIPAR trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 21.1% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 27%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (5 analysts) rates it none, with a mean price target of $109.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 27%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (5 analysts) rates it none, with a mean price target of $109.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $90.25 | +8.9% | · | $1,089 | +8.9% |
| 2 months | $93.00 | +5.7% | · | $1,057 | +5.7% |
| 3 months | $90.03 | +9.2% | $0.80 | $1,100 | +10.0% |
| 6 months | $81.31 | +20.9% | $1.60 | $1,228 | +22.8% |
| 1 year | $135.19 | -27.3% | $3.20 | $750 | -25.0% |
| 2 years | $108.48 | -9.4% | $6.25 | $963 | -3.7% |
| 3 years | $124.07 | -20.8% | $8.88 | $864 | -13.6% |
| 5 years | $68.49 | +43.5% | $12.25 | $1,613 | +61.3% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever IPAR does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.